cyrilzakka/clinical-trials huggingface dataset:
Proactive and Reactive Attention to Negative Templates

EEG Measures during Visual Search Task. In this line of research, the researchers having participants receive a positive (target) template cue, negative (distractor) template cue, or neutral (non-informative) template cue. Note: This is a re-analysis of previously collected data.

When finding a search target, receiving a target cue or distractor cue can increase search efficiency compared to a neutral cue. The researchers are examining the neural basis of visual search when participants receive a positive (target) cue, negative (distractor) cue, or neutral (baseline) cue. Note: This is a re-analysis of previously collected data.

Eligibility Criteria:
Inclusion Criteria:

* normal or corrected to normal visual acuity, normal color vision, no history of neurological disorders

Exclusion Criteria:

-
Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide

The purpose of this study is to evaluate the safety and the efficacy of SMART101 (Human T Lymphoid Progenitors (HTLP)) injection to accelerate immune reconstitution after haploidentical hematopoietic stem cell transplantation (HSCT) with post-transplant cyclophosphamide (PT-Cy) in adult patients with hematological malignancies.


Eligibility Criteria:
Main Inclusion Criteria:

* Patients with AML, ALL or MDS eligible for an allogeneic HSCT with a haploidentical donor with post-transplant cyclophosphamide.
* Patients must be ≥ 18 years of age at the time of signing the ICF.
* Patients must have a Karnofsky index ≥ 70%.
* Patients must have a left ventricular ejection fraction of ≥40%.
* Patients must have an intact pulmonary function or Diffusing capacity of the Lungs for Carbon Monoxide (DLCO) ≥ 45% of predicted.
* Patients must have adequate hepatic and renal functions, as assessed by standard laboratory criteria.

Main Exclusion Criteria:

* Patients who have received prior allogeneic stem cell transplantation.
* Patients who have received prior treatment with another cellular therapy within 4 weeks before the planned day of SMART101 infusion.
* Patients who plan to receive, are concurrently receiving or have received any investigational agent within 4 weeks before the planned day of SMART101 infusion.
AR Ruler to Improve Safety and Clinical Workflow During PICC Placement

The purpose of this study is to assess the utility of an augmented reality virtual ruler during placement of peripherally inserted central catheters.

After being informed about the study, patients who give consent will have their peripheral inserted central catheter placed by a physician wearing mixed reality smart glasses. The mixed reality smart glasses will have an application that allows the physician to measure distances with their hands. This application will be used to measure the appropriate length for which to trim the central catheter.

Eligibility Criteria:
Inclusion Criteria:

* Scheduled for a non-emergent peripherally inserted central catheter placement in Interventional Radiology
* Over 18 years

Exclusion Criteria:

* Undergoing an emergent peripherally inserted central catheter placement
* Younger than 18 years old
Comparison of Intermittent vs. Continuous Walking in MS

Objective: To compare effects of an intermittent and continuous walking program on walking endurance and fatigue in people with multiple sclerosis (MS).A randomized crossover prospective method was used.The intervention consisted of eight 6-minute-long walks (2x/week for 4 weeks). The continuous condition consisted of 6 continuous minutes of walking. The intermittent condition consisted of three 2-minute bouts with 2-minute rests. After a 4-week detraining period, participants performed the second training condition.


Eligibility Criteria:
Inclusion Criteria:

* Positive diagnosis of MS
* Ambulatory for at least 6 minutes with or without an assistive device (e.g. cane, crutches or orthotics)
* Ability to read, understand, and sign an informed consent form

Exclusion Criteria:

* Evidence of exacerbation in the prior three months as defined by a treating physician
* Orthopedic or cardiovascular condition that would interfere with ability to walk for 6 continuous minutes,
* Currently being on an active physical rehabilitation program
Study To Evaluate The Sensitivity Of The Linda Thermal Device

The LINDA thermal device consists of a thermal camera attachable to a cell phone and an application for connection with an artificial intelligence program based on a convolutional neural network for classification of thermographic breast images. The system is previously fed with thermographic images of the breast and their respective results/diagnostics. The images are processed in an automated way and return a percentage of chance of having a pathological pattern.

The LINDA thermal device consists of a thermal camera attachable to a cell phone and an application for connection with an artificial intelligence program based on a convolutional neural network for classification of thermographic breast images. The system is previously fed with thermographic images of the breast and their respective results/diagnostics. The images are processed in an automated way and return a percentage of chance of having a pathological pattern.

nfrared imaging (thermography) was approved as an auxiliary imaging modality for mammography by the Food and Drug Administration (FDA) in 1982. Thermography is a non-invasive, non-contact method without ionizing radiation, which is why its use can be prolonged and repeated. This technique allows for an evaluation of the functionality of the structures, which is why it is considered a physiological test and records the variation in the surface temperature of the human body based on the infrared radiation emitted by the surface of that body. It is capable of detecting tumor lesions since cancer cells generate heat due to the release of nitric oxide in the blood, causing changes in microcirculation, vasodilation, neo-angiogenesis and increased metabolic activity of cancer cells. Thus, in the initial stage of breast cancer, when it has not yet caused anatomical changes, there will be physiological changes that will lead to an increase in blood flow and metabolic activity. This increase induces a temperature rise in the area which will then be detected by thermography.

Eligibility Criteria:
Inclusion Criteria:

1. Provide your signed and dated consent in duplicate;
2. Female, aged between 40 and 69 years;
3. Have had a mammography no more than 6 months before V1 and with results available in V1.

Exclusion Criteria:

1. Fever (temperature above 37.8°C at rest) in the last 48 hours before image capture by thermography;
2. Exposure to natural or artificial light for chest tanning for less than three (3) days before performing the thermography;
3. Pregnant or breastfeeding women in the last 6 months;
4. Physical exercise 3 h before performing the thermography;
5. To have performed a breast biopsy less than 6 months after the thermography;
6. Other conditions that, at the investigator's discretion, increase the risk to the patient or make her unsuitable for the study.
A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer

The purpose of this study is to evaluate the clinical activity of gemcitabine, nab-paclitaxel, capecitabine, cisplatin, and irinotecan (GAX-CI) in patients with metastatic pancreatic cancer.

This was a two-part, single-institution, open-label, dose-escalation, phase 1/2 study to evaluate the clinical activity of gemcitabine, nab-paclitaxel, capecitabine, cisplatin, and irinotecan in patients with metastatic pancreatic cancer.

Part 1 of the study was a Phase 1 3 + 3 dose escalation study designed to evaluate the maximally tolerated dose (MTD) and safety of increasing doses of nab-paclitaxel in combination with gemcitabine, capecitabine, cisplatin, and irinotecan. There were two cohorts of dose escalations. The two cohorts differed based on the treatment cycle length (28 days for Cohort 1 and 21 days for Cohort 2). Dose escalation started with Cohort 1. Enrollment for Cohort 2 dose level 1 began once dose level 2 of Cohort 1 was shown to be safe and did not exceed MTD.

Part 2 was a Phase 2 expansion cohort study for the evaluation of efficacy once the MTD had been determined.

Eligibility Criteria:
Inclusion Criteria:

* Have histologically or cytologically confirmed untreated metastatic pancreatic adenocarcinoma.
* Patients with the presence of at least one measurable lesion.
* Male or non-pregnant and non-lactating female of age \>18 years.
* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
* Patients must have adequate organ and marrow function defined by study-specified laboratory tests.
* Must use acceptable form of birth control while on study.
* Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria:

* Patients who will be considered for surgery are ineligible.
* Patient who have had any prior chemotherapy within 5 years of enrollment.
* Patient who have had radiotherapy for pancreatic cancer.
* Age ≥ 76 years
* Patient who is receiving or have received any other investigational agents within 28 days prior to Day 1 of treatment in this study.
* Patient who has undergone major surgery, other than diagnostic surgery within 28 days prior to Day 1 of treatment in this study.
* Patient who has known brain metastases.
* Patient with history of hypersensitivity or allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine, nab-paclitaxel, capecitabine, cisplatin, or irinotecan.
* Patient with uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
* Patient who has serious medical risk factors involving any of the major organ systems.
* Patient who has known history of infection with HIV, hepatitis B, or hepatitis C.
* Pregnant or breast feeding.
* Patient is unwilling or unable to comply with study procedures
* Patient with clinically significant wound.
Heterologous Boost Immunization with Ad5-nCoV After Three-dose Priming with an Inactivated SARS-CoV-2 Vaccine

This is an open-label, randomized, parallel-controlled clinical trial to evaluate the safety and immunogenicity of heterologous prime-boost immunization with an aerosolized (Ad5-nCoV-IH) or intramuscular (Ad5-nCoV-IM) Ad5-nCoV after three-dose priming with an inactivated COVID-19 vaccine (CoronaVac) in adults aged 18 years and above. A total of 360 subjects will be included. Approximately 210 subjects who have completed three doses of CoronaVac more than 6 months ago in the prior clinical trial and other 150 eligible subjects will be recruited and randomized respectively in a ratio of 1:1:1 to receive a booster dose of Ad5-nCoV-IH or Ad5-nCoV-IM or ICV. The occurrence of adverse reactions within 28 days and serious adverse events within 6 months after vaccination will be observed in all participants. In addition, blood and saliva samples will be collected from all participants on the day 0 before and 14, 28 days and 3, 6 months after the booster vaccination. Each subject will remain in this study for approximately 6 months.


Eligibility Criteria:
Inclusion Criteria:

* Health subjects aged ≥18 years
* The subject can provide with informed consent and sign informed consent form (ICF).
* The subjects are able to and willing to comply with the requirements of the clinical trial program and could complete the 6-month follow-up of the study.
* Participants who have received three-dose of inactivated SARS-CoV-2 vaccine more than 6 months ago.

Exclusion Criteria:

* Have the medical history or family history of convulsion, epilepsy, encephalopathy and psychosis.
* Be allergic to any component of the research vaccines, or used to have a history of hypersensitivity or serious reactions to vaccination.
* Vaccine-related SAE occurred after previous vaccination with COVID-19 vaccine.
* Women with positive urine pregnancy test or in lactation.
* Have acute febrile diseases or infectious diseases or have a history of SARS.
* Axillary temperature\>37.0℃
* Have serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension that cannot be controlled by medication (systolic blood pressure ≥180mmHg and/or diastolic blood pressure ≥110mmHg when measured in the field)
* Have severe chronic diseases or condition is not stable, such as asthma, diabetes, thyroid disease
* Congenital or acquired angioedema / neuroedema.
* Have the history of urticaria 1 year before.
* Have asplenia or functional asplenia.
* Patients with chronic obstructive pulmonary disease, pulmonary fibrosis and other pulmonary abnormalities.
* Have history of SARS-CoV-2 infection or COVID-19.
* Have symptoms of upper respiratory tract infection.
* Have traveled to medium or high risk areas or traveled abroad in the past 21 days, and epidemiologically contacted with SARS-CoV-2.
* Any medical, psychological, social, or other conditions that, in the investigator's judgment, are inconsistent with the protocol or affect the subject's informed consent.
A Noninvasive Arterial Input Estimation Method for O-15 PET and Integrated PET/MR Scanning

The overall aim of this project is to implement a non-invasive method of measuring quantitative regional cerebral blood flow (rCBF) on the UAB hybrid PET/MRI scanner to allow conducting such \[O-15\]water based scans with relative ease and safety in a large variety of important clinical and research applications. Participants will undergo imaging at baseline and after administration of a drug to increase cerebral blood flow to evaluate perfusion estimates during low and high flow states. The goal of this study is to generate data that will justify eliminating invasive arterial sampling in most \[O-15\]water-based PET protocols.


Eligibility Criteria:
Inclusion Criteria:

* Six participants aged 19-60 years of age, male and female, with no evidence of neurological disease, will be recruited from UAB and the surrounding community.

Exclusion Criteria:

* Participants will be excluded if there is any evidence or history of claustrophobia or the subject has metallic implants or devices that are normally exclusion factors for MRI.
Tomosynthesis Mammographic Imaging Screening Trial

A randomized screening trial to compare the diagnostic accuracy of screening for breast cancer with three-dimensional digital breast tomosynthesis (DBT) plus two-dimensional full-field digital mammography (FFDM) versus FFDM alone.

The Tomosynthesis Mammography Imaging Screening Trial (TMIST) LEAD-IN is being conducted to ensure that all Eastern Cooperative Oncology Group / American College of Radiology Imaging Network (ECOG/ACRIN) TMIST components are properly functional and to provide an opportunity for fine tuning before launching the full TMIST. The accrual target for TMIST LEAD-IN is 6354 participants (one tenth of the projected enrollment target for TMIST) at three lead-in study sites: 1. Sunnybrook Health Sciences Centre in Toronto, 2. Vancouver (under the auspices of the Screening Mammography Programme of British Columbia) and 3. The Ottawa Hospital.

Eligibility Criteria:
Inclusion Criteria:

* Asymptomatic women age 40 and over
* Scheduled for screening mammogram
* Able to tolerate digital breast tomosynthesis and full-field digital mammographic imaging required by protocol
* Willing and able to provide a written informed consent.

Exclusion Criteria:

* Presenting for mammography with symptoms of breast disease
* Have new breast complaints (e.g. lump, nipple discharge)
* Have had a mammogram of both breasts within the last 11 months
* Previous personal history of breast cancer
* Has breast enhancements (e.g. implants or injections)
* Pregnancy or intent to become pregnant.
Prospective Constitution of Database Gathering Data of Patients Suffering From Glaucoma Followed at University Hospital of Grenoble

Few publications provide information on the natural history of glaucoma, outside of clinical trials do not always reflect what is observed in common situation for various reasons (specific selection criteria and sometimes restrictive, stronger motivations patients and physicians to comply with follow-up visits and prescribed treatments, etc.). Therefore, much information on the natural history of glaucoma are unknown to date (degradation rate of visual field and visual function over time, risk of blindness in the years following diagnosis, effects of various treatments to reduce intraocular pressure and preserving visual field deterioration, etc.). Obtaining such important data to improve the management of glaucoma patients (choice of treatment methods, identification of predictors of rapid change that can make choosing more aggressive treatment and more regular monitoring, etc.) requires the establishment of cohort of patients followed and treated with the methods usually used in current practice, and besides therapeutic trial.


Eligibility Criteria:
Inclusion Criteria:

* Patients whose age is above 18 years
* Patients with primary or secondary glaucoma or both sides

Exclusion Criteria:

* Major person under guardianship or unable to consent
* Patient Refusal
Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis

This is a randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of 611 when used in combination with topical corticosteroid (TCS) treatment compared with placebo in combination with TCS treatment for moderate-to-severe atopic dermatitis.


Eligibility Criteria:
Inclusion Criteria:

* Male or female adults ages 18 to 75 years old when signing the informed consent.
* AD (according to Hanifin-Rajka Criteria) that had been present for at least 1 years before the screening visit.
* Moderate to Severe Atopic Dermatitis.
* Recent history of inadequate response to treatment with topical medications.

Exclusion Criteria:

* Participation in a prior 611 clinical study.
* Treatment with the following prior to the baseline visit: 1) Systemic corticosteroid or Immunosuppressants / Immunomodulators within 4 weeks or within 5 half-lives (if known), whichever is longer. 2) Monoclonal antibody within 5 half-lives (if known) or 4 months, whichever is longer. 3) Cell-depleting within 6 months.
* Treatment with a live (attenuated) vaccine within 2 months of the baseline visit or planned during the study.
* Serious or Uncontrolled diseases that may affect the safety of participants during the study period or hinder their completion of the study.
* Evidence of active acute or chronic hepatitis.
* History of malignancy within 5 years before the screening visit or currently.
* Pregnant or breastfeeding women, or women planning to become pregnant.
* Any history of vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC).
Enhancing Plasticity in Stroke Patients With Severe Motor Deficit

This study will evaluate the effectiveness of sustained peripheral nerve stimulation coupled with functional motor training, to improve hand motor function in poorly recovered stroke patients. The central hypothesis is that stroke patients with severe motor deficit receiving hand nerve stimulation and intensive task-oriented therapy will have improved motor function compared to patients receiving sham nerve stimulation and task-oriented therapy.

Stroke is one of the most devastating and prevalent diseases, but efforts to limit the amount of tissue damaged in the acute phase have been disappointing, highlighting the need for effective therapeutic interventions after neurologic damage has occurred. Data from animal and human models have suggested that sensory input plays an important role in motor output, possibly by influencing cortical plasticity. However, in spite of the advances to date, little is known about the extent to which sensory input in the form of peripheral nerve stimulation can be successfully combined to physical training especially in poorly recovered stroke patients. This study will evaluate the effectiveness of sustained peripheral nerve stimulation coupled with functional motor training, to improve hand motor function in stroke patients with severe motor deficit. The central hypothesis is that stroke patients with severe motor deficit receiving hand nerve stimulation and intensive task-oriented therapy will have improved motor function compared to patients receiving sham nerve stimulation and task-oriented therapy, and the degree of this behaviorally-measured effect will correlate with the neurophysiological effect measured by transcranial magnetic stimulation.

Eligibility Criteria:
Inclusion Criteria:

* Chronic stroke patients
* Single stroke
* Chronic (more than 12 months after from stroke)
* At least 21 years old, but there is no upper age range for this project.
* Participants NOT able to extend the affected metacarpophalangeal joints at least 10° and the wrist 20°.

Exclusion Criteria:

* History of carpal tunnel syndrome and conditions that commonly cause peripheral neuropathy, including diabetes, uremia, or associated nutritional deficiencies
* History of head injury with loss of consciousness, severe alcohol or drug abuse, psychiatric illness
* Within 3 months of recruitment, use of drugs known to exert detrimental effects on motor recovery
* Cognitive deficit severe enough to preclude informed consent
* Positive pregnancy test or being of childbearing age and not using appropriate contraception
* Participants with history of untreated depression.